DE-CSC
15.11.2022 15:01:43 CET | Business Wire | Press release
CSC, an enterprise-class domain registrar and world leader in mitigating domain and domain name system (DNS) threats, today released its third annual Domain Security Report that found three out of four Forbes Global 2000 companies have not adopted key domain security measures—exposing them to high risk of security threats. These companies have implemented less than half of all domain security measures.
In addition, lookalike domains are targeting those companies as well—with 75% of homoglyph registrations being registered to unrelated third parties. That means many of the world’s largest brands contend with maliciously registered domains that look like their brands. The intent of these fake domain registrations is to leverage the trust placed on the targeted brand to launch phishing attacks or other forms of digital brand abuse, or IP infringement that leads to revenue loss, traffic diversion, and a diminished brand reputation. Homoglyph domains are just some of the endless domain spoofing tactics and permutations that can be used by phishers and malicious third parties.
Additional key takeaways from CSC’s research include:
-
137 companies (6.8%) had a domain security score of “0”
Not deploying any of the recommended domain security measures puts these companies at risk for a variety of attacks, including but not limited to domain and DNS hijacking attacks, network and data breaches, phishing and ransomware attacks, and business email compromise (BEC).
-
45% of companies that use enterprise-class domain registrars also deploy registry lock
Registry lock is a highly cost-effective means to protect domain names against accidental or unauthorized modifications or deletions. Only 5% of companies that use consumer-grade registrars have registry lock deployed. Additionally, only six organizations within the Global 2000 had the highest overall domain security score, which correlates with their use of an enterprise-class registrar.
-
DMARC is the only domain security measure with significantly increased adoption this year
Given all the news about phishing attacks—including their increase in volume and complexity—it’s no surprise that domain-based message authentication, reporting, and conformance (DMARC) adoption has increased by 12 percentage points in the last 12 months. However, growth in other domain security measures, such as registry lock, domain name system (DNS) redundancy, DNS security extensions (DNSSEC), and certificate authority authorization (CAA) records saw limited increases year-over-year.
“This report shows that while some progress has been made, a majority of the companies listed in the Forbes Global 2000 are still overlooking full implementation of foundational domain security measures,” says Mark Calandra, president of CSC’s Digital Brand Services. “A focus on securing legitimate domains while monitoring for malicious domains in parallel needs to be a bigger priority for companies that are advocating for a Zero Trust model to stay protected and thwart cyber risk. Otherwise, companies are exposing themselves to significant enterprise risks that can impact their cyber security posture, data protection, intellectual property, supply chains, consumer safety, revenue, and reputation.”
CSC’s report also found that 82% of the third parties registering homoglyph domains are actively masking their identity. This demonstrates the attempt to hide their ownership, showing they may have some nefarious intentions. Additionally, 48% have MX records in 2022, compared to 43% in 2021. MX records can be used to send phishing emails or to intercept email.
To learn more about CSC’s approach to domain security, visit cscdbs.com. Download the Domain Security Report now at cscdbs.com/securityreport.
About CSC
CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known cybersecurity oversights that exist, and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss, and significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
